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tions increased as the frequency and severity of exacerbations
increased. CONCLUSION: This was the ﬁrst study that gener-
ated COPD-speciﬁc utilities for health proﬁles that included the
health status during exacerbations. Their compatibility with
TTO values of the EQ-5D requires discussion.
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OBJECTIVES: COPD is a cause of high morbidity and mortal-
ity in the population, associated with high individual and social
burden. Projections for 2020 indicate an increase in COPD mor-
tality from the 6th to the 3rd position. Recent discussions 
conducted in the ﬁeld of COPD suggest that achievement of sys-
tematic treatment is accomplished through timely diagnosis of
the disease. Although there is no clear consensus on the treat-
ment patterns for COPD, there is a need to gain a better insight
into approaches of COPD management that better ﬁt the needs
of patients. The aim of this study was to obtain information on
patient perception of the disease, to investigate ways of control
and management of COPD, to examine patient adaptation to
treatment, as well as to assess how COPD affects patients’ life.
METHODS: This study was conducted in 79 primary care physi-
cian (GP/specialists) practices and involved one visit to complete
an extensive questionnaire. The questionnaire contained demo-
graphic data of patients, their symptoms, their pharmaceutical
treatment and their concerns for COPD. RESULTS: In total,
interviewer administered questionnaires were answered by 474
patients (62.7% male, 37.3% female). From those, 53% were
smokers, 97% had symptoms (bronchitis 16.5%, chronic cough
20.3%, asthma 18.4%, chest tightness 11.5%) whereas 80% of
patients received regular pharmaceutical treatment. Satisfaction
from their medication was expressed by 76% of patients,
although 83% express concerns for disease deterioration. 30%
of patients stated that COPD poses an obstacle for their daily
life. CONCLUSIONS: COPD is an impediment for the normal
life of patients. Symptoms are evident, even though patients
receive treatment. Strong concerns from patients themselves are
expressed regarding possible deterioration of their condition.
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OBJECTIVES: Biological therapies are considered effective for
treating chronic plaque psoriasis. We compared two methods of
indirect statistical analyses to assess the relative efﬁcacies of these
treatments. METHODS: A literature search was undertaken to
identify all relevant randomized controlled trials (RCTs) evalu-
ating alefacept, efalizumab, etanercept and inﬂiximab in patients
with psoriasis. Relative risks (RRs) with 95% conﬁdence inter-
vals were calculated for primary outcome measures (i.e., Psoria-
sis Area Severity Index (PASI)75 response rates at week 10/12)
using the Mantel-Haenszel method. Heterogeneity was estimated
across trials, and the null hypothesis (study effects were homo-
geneous) was tested. Treatments were also compared in an evi-
dence synthesis with endpoints jointly modeled using an ordered
probit model. This mixed treatment comparison was imple-
mented as a Bayesian hierarchical model. RESULTS: A compar-
ison of predicted probabilities and relative risks with the
Mantel-Haenszel calculated results indicated a good ﬁt for the
Bayesian model. In terms of RR compared to placebo, inﬂiximab
is the most effective for the PASI 75 response (Mantel-Haenszel
Relative Risk (MHRR) 18.23, 95%CI 8.45 to 39.34; Bayesian
Relative Risk (BRR) 20.53, Bayesian Conﬁdence Interval (BCI)
16.75 to 25.05). The next most effective was etanercept 50 mg
(MHRR 11.92, 95%CI 8.17 to 17.39; BRR 12.39, BCI 10.10 to
15.12) followed by etanercept 25 mg (MHRR 10.68, 95%CI
6.15 to 18.57; BRR 8.87, BCI 7.02 to 11.10) then efalizumab
(MHRR 7.47, 95%CI 5.20 to 10.73; BRR 7.27, BCI 5.88 to
8.92) then alefacept (MHRR 3.37, 95%CI 2.18 to 5.23; BRR
4.49, BCI 3.44 to 5.79). The ordering of effectiveness seen in
PASI 75 response was reﬂected in results for other outcomes (i.e.,
PASI 50, 90 and response rates). CONCLUSIONS: Two statis-
tical methods for meta-analysis give comparable results and
demonstrate that inﬂiximab is signiﬁcantly more effective at
week 10/12 than other currently available biological therapies
for chronic plaque psoriasis.
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OBJECTIVE: Biologics have the most favorable clinical proﬁle
required for the management of moderate to severe psoriasis.
However, costs and patients’ adherence related to biologics are
important factors to consider while making informed decisions
regarding the biologics therapy in psoriasis management. This
study examined predictors of biologics related adherence, total
health care costs, and service utilization among psoriasis patients
enrolled in Medicaid program. METHODS: This was a longitu-
dinal cohort study of psoriasis patients (<65 years old) enrolled
in North Carolina Medicaid who were prescribed one of the bio-
logics (alefacept, efalizumab, and etanercept) approved by the
US Food and Drug Administration during the study period.
Patients’ medication adherence, total health care costs, and
service utilization (hospitalizations, inpatient and outpatients
visits) patterns in pre- and post-biologics period were examined.
RESULTS: Adherence to biologics was signiﬁcantly higher as
compared with the other psoriasis medications (0.66 vs. 0.39; P
< 0.001). Prescription drug costs was signiﬁcantly higher in 
the post-biologics period ($3796.77 vs. $11706.32; p < 0.001).
However, total health care costs in the post-biologic period did
not differ signiﬁcantly from pre-biologic period ($14,662.22 vs.
$16,156.1; p > 0.05). Patients’ adherence and health care costs
did not differ signiﬁcantly across biologics. After controlling for
other variables, patients had signiﬁcantly lower number of hos-
pitalizations in the post-biologic period (p < 0.001). Adherence
related to psoriasis medications (biologics and other psoriasis
medications) remained the strongest predictors of number of ED
visits in the study cohort (both p < 0.001) CONCLUSIONS:
Although costs associated with biologic prescriptions were
higher, total health care costs did not differ signiﬁcantly in the
post-biologics period. Biologics had a better adherence rate as
compared to other psoriasis medications. Increased medication
adherence was associated with a lower number of ED visits.
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Further investigations using larger cohorts are warranted to
better understand economic and patient-reported outcomes asso-
ciated with biologic treatment in psoriasis.
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OBJECTIVES: Biologic therapies have been shown to be a safe
and effective treatment for chronic plaque psoriasis. However,
there appear to be notable differences in effectiveness between
treatment options. Given the considerable costs of these treat-
ments, their relative cost-effectiveness is an important consider-
ation. METHODS: A cost-effectiveness model was developed to
estimate the incremental cost per responder associated with each
biologic licensed in the UK for psoriasis. Data on response,
deﬁned as Psoriasis Area Severity Index (PASI) 75 or 90, were
derived from randomized controlled trials for efalizumab, etan-
ercept and inﬂiximab. An ordered probit model was used to
model response rates jointly. Treatment effects, deﬁned as
response rates, and direct health care costs from published
sources were modelled over a 1-year time-horizon. Costs
included in the analysis comprised drug acquisition, monitoring
and administration costs, as well as costs associated with out-
patient and inpatient hospital episodes. Treatment non-
responders were assumed to receive best supportive care. All
licensed regimens were included as potential treatment options.
RESULTS: In the analysis utilising PASI 75 response, efaluzimab
and etanercept 25 mg twice weekly (BIW) continuous, were dom-
inated by other regimens. Of the remaining strategies, etanercept
25 mg BIW had the lowest ICER vs. supportive care (response
rate 31.78%, £8891 per responder gained), followed by inﬂix-
imab (78.79%, £11,302) and then etanercept 50 mg continuous,
(45.99%, £12,598). For PASI 90 response, the same two strate-
gies were dominated. However inﬂiximab was the most effective
and had the lowest ICER vs. supportive care (response rate
56.65%, £15,721 per responder gained) followed by etanercept
25 mg BIW (12.34%, £22,907) then etanercept 50 mg continu-
ous, (21.58%, £26,853). CONCLUSIONS: Provided decision-
makers are willing to pay up to approximately £12,000 to gain
an additional PASI 75 responder and also value clearance of
symptoms (PASI 90 responder), treatment with inﬂiximab is
likely to represent the most cost-effective strategy.
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OBJECTIVES: UVB phototherapy is an effective treatment for
psoriasis, typically introduced after a patient with widespread
disease has failed to respond to a couple of topical agents. A
pharmacoeconomic model was devised to analyse the cost impli-
cations of different treatment combinations based on a Scottish
model of care. METHODS: A calcipotriol/betamethasone dipro-
pionate two-compound product was assessed alongside two of
the UK’s most commonly prescribed topical antipsoriatic agents
(calcipotriol and betamethasone valerate in several different
treatment regimens to determine the most cost-effective treat-
ment A Markov chain approach was used to model the pro-
gression of psoriatic patients through the response or non-
response to 4 weeks treatment with different topical agents. The
patient pathway consisted of two four-week treatments with ﬁrst
and second line topical agents before referral to secondary care
and phototherapy. Non-responders (i.e. those who did not
achieve PASI-75) on ﬁrst line treatment were then given a second
line topical agent. Those who failed again were referred to sec-
ondary care and waited 6 months before completing 20 treat-
ments of phototherapy. One hundred patients were evaluated in
each of the six different treatment pathways over one year to
determine overall cost per patient. RESULTS: Mean annual cost
per patient showed that the most cost-effective treatment
regimen used the two compound product as ﬁrst and second line
treatments. It was 19.7% cheaper (≤690.99 vs ≤860.62) and
32% fewer patients required phototherapy (30 vs 44) when com-
pared to the next best regimen which used the two-compound
product and calcipotriol as ﬁrst and second line treatments
respectively. CONCLUSION: This pharmacoeconomic evalua-
tion demonstrates that the two-compound product, when used
as an initial therapy in psoriasis, could result in a reduction in
overall costs per patient and in fewer patients requiring pho-
totherapy. This in turn, could improve access to phototherapy
for more patients with light-responsive dermatoses.
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OBJECTIVES: The aim of the Costi-&-Outcomes-in-Dermatite-
Atopica (CODA) study was to evaluate the socioeconomic
impact of AD. METHODS: The CODA study was a naturalis-
tic, multicentre, longitudinal ambispective (retro-prospective),
prevalence based Cost Of Illness study. Data on patients with
moderate or severe AD enrolled during ﬂare-up was collected:
socio-demographic, clinical (SCORing-Atopic-Dermatitis index
(SCORAD): 0 = no disease; 100 = maximum manifestation) eco-
nomic (direct and indirect costs), HRQoL (intangible costs),
preferences towards pharmacological treatment. The following
results pertain to the economic burden of AD and its treatment
in adult patients. The analysis was conducted from the societal
perspective with a 3 month time horizon. Direct medical costs
(hospitalizations, drugs, cosmetics, personal health supplies, spe-
cialist visits, diagnostics and laboratory exams) were quantiﬁed
using prices or tariffs expressed in Euro 2005. Also indirect cost,
in terms of productivity losses by patients, were calculated using
human capital approach. RESULTS: We erolled 104 valid adults
from 6 Italian dermatological referral centres (males 53.8%,
mean age = 32.9 ± 11.8 y.o.). At the enrolment the median
SCORAD was 52.0 while after 2 months was 18.0 (p < 0.0001
Wilcoxon Signed Rank test). Direct cost/patient/month was at
baseline 369.6 ± 440.0€: 28.8% hospitalizations, 19.9% drugs,
16.0% cosmetics. After 2 months from the enrolment direct
cost/patient/month was €188.1 ± €236.1: 42.5% drugs, 35.2%
cosmetics, 8.8% hospitalizations. The decrease in direct cost
during the follow up period was statistically signiﬁcant (p = <
0.0001 paired samples t test). Indirect cost/patient/month was
€247.0 ± €626.5 at baseline and €32.8 ± €106.1 after 2 months
(p = < 0.0001). CONCLUSION: This is the ﬁrst study evaluat-
ing the socio-economic impact of AD in Italy. The difference
between cost during relapse period and after 2 months is signif-
icant. Among adult patients hospitalisations and drugs are the
cost drivers at baseline and after 2 months respectively. High cost
